Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

DUBLIN--()--The "Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Disease Overview

Hemophilia is a genetic disorder characterized by excessive bleeding and delayed blood clotting. There are two types of hemophilia, hemophilia A (also known as classic hemophilia) and hemophilia B.

According to the Centers for Disease Control and Prevention, the incidence of hemophilia stands at, one out of every 5,000 male births and as many as 20,000 males in the U.S., living with either of the two types of hemophilia, presently. The prevalence of hemophilia A is around four times high as compared to the prevalence of hemophilia B.

It has been observed that the male population is more commonly affected by the disease, as compared to the female population, since hemophilia is inherited in an X-linked recessive genetic pattern, where females are generally carriers of the disease.

Pipeline Analysis

Significant growth is expected in the therapeutic pipeline of hemophilia, mainly attributed to increasing collaboration between pharma as well as biotech companies, educational institutes and associations for the development of hemophilia therapeutics.

Increasing prevalence of hemophilia and technological advancement are some of the major factors for the development of novel therapies for treatment of hemophilia. Positive clinical results of Phase III and Phase II drug candidates with lesser side effects are supporting the development of hemophilia therapeutics.

Many awareness programs organized by pharma as well as biotechnology companies are supporting the development of hemophilia therapeutics pipeline.

Key players (developing drugs for the treatment of hemophilia)

  • Sangamo BioSciences, Inc.,
  • Caisson Biotech, Inc.,
  • XL-protein GmbH
  • and others.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Hemophilia Therapeutics Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/89gkmz/hemophilia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Hematological Drugs